Stimuli-Responsive Nanocarriers as Next-Generation on-Demand Drug Delivery Systems for Cancer Therapy: Mechanistic Insights, Trigger Modalities, and Translational Challenges
Abstract
Chemotherapy has been used in cancer treatment for decades; however, standard chemotherapy treatments still have significant weaknesses, including collateral damage to healthy tissue, rapid development of drug resistance, and dose-limiting toxicity that limits therapeutic value. There is now an alternative approach using polymer materials that are responsive to biological stimuli that will allow for improved treatment of cancer while avoiding the limitations. Responsive polymer materials are designed to be inert during circulation until they reach their site of action; then, they will respond to specific triggers. These smart carriers respond to stimuli present in the tumor microenvironment (e.g., low pH, high glutathione levels, and increased proteolytic activity) or external stimuli applied at the bedside (e.g., localized heat, light, ultrasound, and applied magnetic fields). In both cases, there is a consistent pattern where the drug is released exactly where/when it is needed, with minimal drug release occurring outside that location and timeframe. Therefore, it is theorized that the use of polymeric-based delivery systems with stimuli-regulated drug release will significantly increase the concentration of drug delivered intratumorally, decrease the drug toxicity, and provide a potential mechanism to overcome the development of multidrug resistance from a variety of cancer treatments. To date, various types of responsive polymers have been developed and could be combined…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.